ES2033985T3 - Un procedimiento para la preparacion de una composicion farmaceutica. - Google Patents

Un procedimiento para la preparacion de una composicion farmaceutica.

Info

Publication number
ES2033985T3
ES2033985T3 ES198888105821T ES88105821T ES2033985T3 ES 2033985 T3 ES2033985 T3 ES 2033985T3 ES 198888105821 T ES198888105821 T ES 198888105821T ES 88105821 T ES88105821 T ES 88105821T ES 2033985 T3 ES2033985 T3 ES 2033985T3
Authority
ES
Spain
Prior art keywords
procedure
preparation
pharmaceutical composition
amides
esters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198888105821T
Other languages
English (en)
Inventor
Soonih Kim
Kazuhisa Takeda
Seiei Sasatani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2033985T3 publication Critical patent/ES2033985T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVAS COMPOSICIONES FARMACOLOGICAS QUE SE CARACTERIZAN PORQUE HAY ESTERES O AMIDAS O UNA MEZCLA DE ELLOS SUSPENDIDOS O DISUELTOS EN UN GLICERIDO DE CADENA MEDIA. ESTAS COMPOSICIONES FARMACOLOGICAS INHIBEN LA DEGRADACION DEL INGREDIENTE ACTIVO (ESTO ES, LOS ESTERES O LAS AMIDAS) POR LA ACCION DE VARIAS ENZIMAS DIGESTIVAS EN EL APARATO DIGESTIVO.
ES198888105821T 1987-04-13 1988-04-12 Un procedimiento para la preparacion de una composicion farmaceutica. Expired - Lifetime ES2033985T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8878587 1987-04-13

Publications (1)

Publication Number Publication Date
ES2033985T3 true ES2033985T3 (es) 1993-04-01

Family

ID=13952501

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198888105821T Expired - Lifetime ES2033985T3 (es) 1987-04-13 1988-04-12 Un procedimiento para la preparacion de una composicion farmaceutica.

Country Status (7)

Country Link
US (3) US4889723A (es)
EP (1) EP0287036B1 (es)
KR (1) KR880012221A (es)
AT (1) ATE62419T1 (es)
DE (1) DE3862337D1 (es)
ES (1) ES2033985T3 (es)
GR (1) GR3001762T3 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1263840B (it) * 1993-03-30 1996-09-04 Giuseppe Furiosi Formulazioni orali di ubidecarenone in forma di capsule
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
WO1997037969A1 (fr) * 1996-04-10 1997-10-16 Ono Pharmaceutical Co., Ltd. Inhibiteur de tryptase derives de guanidino
ES2322405T3 (es) * 1996-07-08 2009-06-19 Penwest Pharmaceuticals Co. Matriz de liberacion controlada para farmacos insolubles en dosis elevadas.
AU719076B2 (en) * 1996-12-19 2000-05-04 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
ES2211151T3 (es) * 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
AU769429C (en) 1998-12-30 2004-10-28 Dexcel Limited Dispersible concentrate for the delivery of cyclosporin
WO2000051623A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
WO2000051625A1 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
ATE391495T1 (de) * 1999-09-30 2008-04-15 Penwest Pharmaceuticals Co Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
US7850970B2 (en) 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
WO2006047476A2 (en) * 2004-10-26 2006-05-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
MX356017B (es) 2011-09-29 2018-05-08 Plx Opco Inc Portadores dependientes de ph para la liberacion dirigida de productos farmaceuticos a lo largo del tracto gastrointestinal, composiciones de los mismos, y fabricacion y uso de las mismas.
AU2021244695A1 (en) 2020-03-26 2022-11-10 Plx Opco Inc. Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE45448B1 (en) * 1976-07-12 1982-08-25 Kali Chemie Pharma Gmbh Enterally highly-absorbable preparations of cardiac glycosides which by themselves are absorbable with difficulty and process for the production of such preparations
JPS53136513A (en) * 1977-05-06 1978-11-29 Ono Pharmaceut Co Ltd Stabilization of prostaglandin-x-related compounds
SE445174B (sv) * 1978-03-07 1986-06-09 Sandoz Ag Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
DE3000377A1 (de) * 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US4305936A (en) * 1980-10-09 1981-12-15 Dermik Laboratories Topical corticosteroid formulations
DE3042975A1 (de) * 1980-11-14 1982-09-09 Lucas Meyer GmbH & Co, 2000 Hamburg Mikrodispersion mit einem wirkstoff und/oder einem reagens in salzform als disperser phase
JPS57197214A (en) * 1981-05-29 1982-12-03 Tanabe Seiyaku Co Ltd Rapid-releasing microcapsule and its preparation
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
DE3411910A1 (de) * 1984-03-30 1985-10-10 Warner-Lambert Co., Morris Plains, N.J. Galenische zubereitung
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4716178A (en) * 1985-07-22 1987-12-29 Riker Laboratories, Inc. Substituted di-t-butylphenols

Also Published As

Publication number Publication date
US5004612A (en) 1991-04-02
US4889723A (en) 1989-12-26
DE3862337D1 (de) 1991-05-16
KR880012221A (ko) 1988-11-26
ATE62419T1 (de) 1991-04-15
EP0287036A3 (en) 1988-11-30
US5110602A (en) 1992-05-05
GR3001762T3 (en) 1992-11-23
EP0287036B1 (en) 1991-04-10
EP0287036A2 (en) 1988-10-19

Similar Documents

Publication Publication Date Title
ES2033985T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica.
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
BG103335A (en) Application of fumaric acid derivatives
FI960504A (fi) Menetelmä terapeuttisten yhdisteiden ja rasvahappojen muodostamien konjugaattien valmistamiseksi
ES2018478B3 (es) Un sistema para preparar una composicion desensibilizante dental.
DK442287A (da) Farmaceutisk praeparat indeholdende l-3,4-dihydroxyphenylalanin (l-dopa) som aktiv bestanddel og fremgangsmaade til fremstilling af et saadant praeparat
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
IT1187687B (it) Composizioni farmaceutiche contenenti come principi attivi flavanolignani e fosfolipidi
FI914409A0 (fi) Kalciumupptagande inhibitorer.
ATE45091T1 (de) Pharmazeutische zubereitung mit speziellen 1,2diacyl-glycero-3-phosphocholinen zur behandlung von erkrankungen im magen-darmbereich.
ZA898331B (en) Pharmaceutical compositions
ES2069915T3 (es) Dicarbonatos y uretanos de los acidos 4,5-dihidroxi- y 4,5,8-trihidroxi-9,10-dihidro-9,10-dioxo-2-antracenocarboxilicos que tienen actividades terapeuticas.
BG88028A (bg) Амиди на циклометилен-1,2-дикарбоксилни киселини с терапевтична активност,методи за получаването им и фармацевтични състави, които ги съдържат
RU95113437A (ru) (h±)-сложный этиловый эфир транс-2-диметиламино-1-фенил-3-циклогексентранс-1-карбоновой кислоты в виде первичного ортофосфата и твердая фармацевтическая композиция с обезболивающей активностью
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.
ES2054904T3 (es) Procedimiento para la preparacion de peptidos con actividad inhibidora de sistemas enzimaticos.
NO883520D0 (no) Fremgangsmaate for fremstilling av et injeksjonspreparat.
ES2054790T3 (es) Compuestos que tienen actividad cardiovascular.
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
MX9207543A (es) Sales estables de acido (+)-(1s,2r)-[[b.(2-hidroxilamino-2-oxoetil)-n-metilamino]carbonil]cicl ohexan-1-carboxilico, procedimiento para su preparacion, y composiciones farmaceuticas que las contienen
FI914410A0 (fi) Kalciumupptagande inhibitorer.
ATE15331T1 (de) Verfahren fuer die orale verabreichung von substanzen in der form von liposomen, und ihre pharmazeutischen zusammensetzungen.
KR880010762A (ko) 소화성궤양의 치료방법 및 치료용 합성물(Composition and Method for Treatment of peptic Ulcers)
ES2055440T3 (es) Derivados del acido quinurenico, su preparacion y composiciones farmaceuticas que los contienen.
ES2059594T3 (es) Peptidos con actividad inhibidora de sistemas enzimaticos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 287036

Country of ref document: ES